Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Azemist
- Development stage
- Phase 4
- Lead developer
- Kaizen Drugs
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
**Azemist** is a marketed metered-dose intranasal fixed-dose combination of azelastine hydrochloride 0.1% and fluticasone propionate 0.0357%, manufactured by Kaizen Pharmaceuticals. It combines an H1 antihistamine with an intranasal corticosteroid for symptomatic treatment of allergic rhinitis, including nasal congestion, sneezing, rhinorrhea, and nasal itching. Azelastine inhibits histamine H1 receptor-mediated allergic symptoms, while fluticasone propionate activates glucocorticoid receptors to suppress inflammatory-cell and inflammatory-mediator activity in the nasal mucosa. ([kaizenpharmaceuticals.in](https://kaizenpharmaceuticals.in/product/azemist/))
- Brand names
- Azemist
02
Targets
GR (Glucocorticoid receptor)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on Azemist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Azemist.